Genetix Pharmaceuticals (Columbia) Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer (9/9/2010)

Genetix Pharmaceuticals (now bluebird bio) is a Columbia spinoff developing innovative gene therapies for severe genetic disorders.

bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced that it has changed the company name from Genetix Pharmaceuticals, Inc., to bluebird bio, Inc., effective immediately. In addition, bluebird bio has also announced that Nick Leschly, formerly interim president of bluebird bio and partner of Third Rock Ventures, has been appointed the company’s president and chief executive officer. [read more]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: